Abstract: This invention relates to a chamber in which a chemical reaction is carried out in the presence of catalyst and reagents, comprising at least one catalytic tube (10) into which is placed an internal tube (12) for evacuating the gas that is produced, means for introducing reagents (15) and means for introducing the catalyst (16) that are located in the upper portion of the chamber (1), means for heating the catalytic tube (10) that are arranged in the lower portion of the chamber (1), and in which the catalytic tube (10) comprises, in its upper portion above the catalyst (13), means that promote heat exchange between the reagents and the gas that is produced. The invention also relates to the process that uses this chamber.

Abstract: Novel compounds of the formula (I), in which D, E, G, W, X, Y, T, R1 and R2 are as defined in Patent Claim 1, are inhibitors of coagulation factor Xa and can be employed for the prophylaxis and/or therapy of thromboembolic diseases and for the treatment of tumors.

Abstract: A semiconductor device including a semiconductor 1, a first electrode 2, an insulating layer 3 interposed between the semiconductor 1 and the first electrode 2, the second electrode 4 which is in contact with the semiconductor 1 and is detached from the first electrode 2, and the third electrode 5 which is in contact with the semiconductor 1 and is detached from the first electrode 2 and the second electrode 4, wherein the semiconductor 1 is provided with the organic semiconductor layer 10 and the oxide semiconductor layer 11.

Abstract: Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.

Abstract: The present invention relates to the provision of the genetic sequence of the major grass pollen allergen Phl p 4. The invention also covers fragments, new combinations of partial sequences and point mutants having a hypoallergenic action. The recombinant DNA molecules and the derived polypeptides, fragments, new combinations of partial sequences and variants can be utilised for the therapy of pollen-allergic diseases. The proteins prepared by recombinant methods can be employed for the in vitro and in vivo diagnosis of pollen allergies.

Abstract: The present invention is related to compounds for use in liquid crystal media, liquid crystal media comprising said compounds, the use of said media in electro-optical devices, said electro-optical devices, and the use of said compounds in mesogenic media for use in electro-optical devices that may be operated in an optically isotropic state.

Abstract: The invention relates to a crystallized solid, denoted by the name IM-16, which has an X-ray diffraction pattern as provided hereinafter. Said solid has a chemical composition expressed in accordance with the empirical formula mXO2:nGeO2:pZ2O3:qR:sF:wH2O, where R represents one or more organic species, X represents one or more tetravalent elements different from germanium, Z represents at least one trivalent element and F is fluorine.

Abstract: In a process for the preparation of ring compounds via a combinatorial synthesis, the reaction procedure is based on a Suzuki coupling, subsequent halo-demetallation and finally a further Suzuki coupling. The Suzuki couplings are each carried out with a boronic acid or a boronic acid ester. The reaction procedure uses provides novel ring compounds and uses novel synthesis units used for this purpose. The novel ring compounds are suitable for use as constituents in liquid-crystalline mixtures.

Abstract: A process for separating a feed F by simulated moving bed adsorption in a SMB device comprises at least one zone 1 for desorption of the compounds produced in the extract, a zone 2 for desorption of the compounds produced in the raffinate, a zone 3 for adsorption of the compounds produced in the extract, a zone 4 located between the raffinate withdrawal and the desorbant supply, the device comprising external by-pass lines Li/i+1 directly connecting two successive plates Pi and Pi+1; in which the degree of opening of means for restricting the flushing flow rate of the by-pass lines Li/i+1 are sequentially modified such that: 1) in an operational zone where there is at least one closed by-pass line, a super-synchronicity of the flushing flow rate is established in all of the by-pass lines which are not closed belonging to the zone under consideration, said super-synchronicity being defined by the following formula: S=a+b(nf/nt) in which the constant a is a constant in the range ?5 to 5 and b is a constant

Abstract: Compounds according to formula (I): wherein R1, R2, R3, n and X are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful for the modulation of CCR5 chemokine receptor activity. Additionally, compounds according to Formula III: wherein Z, R?1, and R?2 are defined as defined herein, and the pharmaceutically acceptable salts, hydrates and solvates thereof, are useful as intermediates for production of compounds that modulate CCR5 chemokine receptor activity.

Abstract: A process for separating a feed F by simulated moving bed adsorption in a SMB device is described, the device comprising external bypass lines Li/i+1 which directly connect two successive plates Pi, Pi+1, the index i being either even or (exclusive of the foregoing) odd, along the whole length of the column, in order to flush said plates, in which each of the bypass lines Li/i+1 comprises automated means for regulating the flow rate in the bypass lines, the degree of opening of said regulating means being defined by the following three rules: a) establishing a flow rate corresponding to an oversynchronicity in the range 15% to 30% in all of the open bypass lines of zone 1; b) establishing a flow rate corresponding to the synchronicity to within plus or minus 8% in all of the open bypass lines of zones 2 and 3; c) establishing a flow rate corresponding to an oversynchronicity in the range 20% to 40% in all of the open bypass lines of zone 4.

Abstract: The present invention relates to a process for preparing 4-{4-[({[4-chloro-3-(trifluoro-methyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methylpyridine-2-carboxamide and its tosylate salt.

Abstract: A process for separating a feed F by simulated moving bed adsorption in a SMB device comprises external bypass lines Li/i+1 which directly connect two successive plates, Pi, Pi+1, the index “i” being either even or (exclusive of the foregoing) odd, along the whole length of the column, allowing said plates to be flushed, in which each of the bypass lines Li/i+1 comprises automated means for regulating the flow rate in the bypass lines, the bypass lines in certain cases being subject to a flushing flow during injection or withdrawal operations.

Abstract: This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.

Abstract: An organic semiconducting layer formulation containing an organic binder which has a permittivity, ?, at 1,000 Hz of 3.3 or less and a polyacene compound of Formula A: and processes for the preparation thereof and uses thereof in various electronic devices.

Abstract: Novel compounds of the formula I (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R, Q, W, X and Z have the meanings indicated in Patent Claim 1, are suitable as antidiabetics.

Abstract: The invention relates to a birefringent layer having negative optical dispersion, a liquid crystal (LC) medium for its preparation, and the use of the birefringent layer and the LC media in optical, electrooptical, electronic, semiconducting or luminescent components or devices.

Abstract: Novel triazole derivatives of the formula (I) in which R1-R6 and Y have the meanings indicated in Claim 1, are HSP90 inhibitors and can be used for the preparation of a medicament for the treatment of diseases in which the inhibition, regulation and/or modulation of HSP90 plays a role.

Abstract: The invention relates to a novel catalyst having excellent activity and selectivity for reducing nitric oxides (NO/NO2) to nitrogen gas (N2) with hydrogen (H2) being used as a reducing agent under strongly oxidizing conditions (e.g., 2-10 vol % O2) (H2-SCR) in the 100-400° C. range, but in particular to the low-temperature range 100-200° C. The inventive catalyst is a combination of platinum and palladium which are in contact with solid phases of a mixed MgO and CeO2 medium.

Abstract: The present invention relates to pearlescent pigments based on flake-form substrates which have at least one FeOOH layer and at least one TiO2 layer or at least one TiO2/SiO2/TiO2 layer package, and to the use thereof, inter alia, in paints, coatings, printing inks, powder coatings, plastics and in particular in care and decorative cosmetics.